Loading video...
Summary
The Rules Committee convened to consider H.R. 27, the Halt Fentanyl Act, which aims to permanently place fentanyl analogs into Schedule I of the Controlled Substances Act to curb illicit trafficking. Witnesses, including Representatives Griffith and DeGette, testified on the bill's potential to deter fentanyl cartels by eliminating legal loophholes, its research provisions, and the public health and safety implications. While proponents argue the legislation strengthens enforcement and allows scientific study of fentanyl analogs, critics contend it is a narrow, partisan effort that fails to address the root causes of addiction or funding cuts to public health programs. The hearing also highlighted bipartisan concerns about the Trump administration's attempts to freeze federal funding for substance abuse programs, which critics view as undermining efforts to combat the fentanyl crisis. The bill's adoption was ultimately secured through a procedural motion, with amendments failing to gain traction amid divisions over its scope and impact on public health initiatives.
Participants
Transcript
Sign up for free to see the full transcript
Accounts help us prevent bots from abusing our site. Accounts are free and will allow you to access the full transcript.